

(12) **UK Patent Application** (19) **GB** (11) **2 153 830 A**
(43) Application published 29 Aug 1985

(21) Application No **8503249**

(22) Date of filing **8 Feb 1985**

(30) Priority data

(31) **579492** (32) **13 Feb 1984** (33) **US**

(71) Applicant
**Damon Biotech Inc. (USA-Delaware),
119 Fourth Avenue, Needham Heights,
Massachusetts 02194, United States of America**

(72) Inventors
**Randall G. Rupp,
Scott Geyer**

(74) Agent and/or Address for Service
**Graham Watt & Co.,
Riverhead, Sevenoaks, Kent TN13 2BN**

(51) INT CL⁴
C07K 15/06

(52) Domestic classification
**C3H F5
U1S 2419 C3H**

(56) Documents cited
None

(58) Field of search
C3H

INF. C12P21/00E

(54) Protein production method

(57) A method of improving protein production in protein-producing cell cultures, e.g. for producing antibodies, comprises the steps of culturing the cells in a medium modified by the addition of increased amounts of amino acids so that the osmolarity of the medium is hypertonic, i.e., above about 340 milliosmoles.

2153330




FIG. 1

2153330






FIG. 2






FIG. 5

SPECIFICATION

Protein production method

- 5 This invention relates to a method of improving protein production, and more particularly antibody production, in animal cell cultures. Briefly, hypertonic rather than isotonic media are used to feed and maintain the cells. This has the effect of increasing the amount of protein produced per cell while maintaining cell viability. Such hypertonic media are especially well suited for growing antibody-producing cells such as hybridoma since such cells produce much more antibody without significant modification of
- 10 their viability or growth rate.
- Conventional media for cultivation of mammalian cells are formulated in accordance with Eagle's two seminal papers on the effect of ion concentration on cell growth cycles, *see Science*, 122: 501-4(1955) and *Arch. Biochem. & Biophys.*, 61:356-66 (1956). Eagle determined that media containing 85-115 mM sodium and 1-10 mM potassium were optimum for growth of both HeLa cells and mouse fibroblasts. The
- 15 formulation of Eagle's basal medium, which forms the basis for almost all animal cell growth media used today, is based on these results.
- Eagle's work was followed by Stubblefield and Mueller, *see Cancer Res.* 20: 1646-1655 (1960), who explored the effects of sodium chloride concentration on growth, biochemical composition, and metabolism of HeLa cells. Stubblefield discovered that higher concentrations of sodium chloride in the growth medium
- 20 prevented cell replication, leading to a decrease in the number of cells, while promoting RNA and protein synthesis in the cells that survive. Stubblefield theorized that the change in saline content hindered DNA replication thereby preventing mitosis and permitting the cells which survived to grow larger than they otherwise would. The addition of sodium chloride changed the osmolarity of the medium but Stubblefield did not attempt to differentiate between osmotic and ionic effects.
- 25 Twelve years later, Schachtschabel and Foley (*see Exp. Cell Res.* 70: 317-324, 1972) cultured Ehrlich ascites tumor cells in media made hypertonic by the addition of sodium chloride to determine the effect of high tonicity media on the growth cycle of this type of cells. Schachtschabel found that a salt-tolerant population which followed a substantially normal life cycle developed after significant losses in the number of cells in the culture. However, these salt-tolerant cells had a somewhat different morphology than conventional cells,
- 30 i.e., they appeared more like fibroblast than epithelial cells. The generation or doubling time for these cells increased dramatically and the number of surviving cells decreased as the tonicity of the media was increased.
- Antibody-producing cultures, e.g., spleen cells and hybridomas, are normally grown in media such as Eagle's modified media containing serum. Growth cycles for the antibody-producing cells in these media
- 35 and the amount of antibody secreted is within the expected range as compared with other protein-secreting cells grown in these media. However, the increased use of antibodies as biological tools, particularly through the advances in hybridoma and monoclonal antibody formation techniques, have led to a need for increased antibody production from specific cell cultures.
- Myelomas are also grown normally in isotonic media. Since these cells produce protein and can be
- 40 genetically modified, a medium which could increase protein production level without loss of cell viability would be advantageous.
- Accordingly, an object of the invention is to provide a method of culturing protein-producing cells to improve protein production. Another object is to promote high antibody production from antibody-producing cells while developing a viable, expanding culture. It would be desirable to promote hybridoma
- 45 growth and monoclonal antibody production without adding feeder cells to the culture. It would be industrially advantageous to provide a method of obtaining high protein yields from large volume cultures containing a high density of cells, e.g., myeloma, while retaining cell viability.
- The present invention provides a method of promoting protein or antibody production from a protein or antibody-producing cell of mammalian origin comprising the step of culturing the said cell in a hypertonic
- 50 medium having an osmolarity no less than about 340 milliosmoles.
- The invention also provides a medium for promoting protein production from protein-producing cells, wherein the said medium contains essential salts, nutrients, vitamins, and amino acids, and wherein the medium further comprises additional amino acids sufficient to increase the osmolarity of the medium to about 340 to 450 milliosmoles.
- 55 The invention will now be described in more detail by way of example only with reference to the accompanying drawings, in which
- Figure 1* is a graph which illustrates the effect on cell population of media made hypertonic by amino acid addition for a culture of antibody-producing cells;
- Figure 2* is a graph which illustrates the viability of cells grown in the media of *Figure 1*;
- 60 *Figure 3* is a graph which illustrates antibody production from cultures grown in the media of *Figure 1*;
- Figure 4* is a graph which illustrates that sodium chloride can be used to make the medium hypertonic without loss of cell viability; and
- Figure 5* illustrates apparatus useful in producing protein in accordance with the invention.
- The invention features a method of promoting protein production, especially antibody production, in
- 65 animal cell cultures. In brief, it has been discovered that conventional media used for culturing

protein-producing cells can be modified to promote significantly higher protein yields with higher specific activity than has previously been possible. The invention also features an improved growth medium which promotes protein production.

The method of promoting protein production involves culturing a protein-producing cell in a hypertonic medium, that is, a medium having an osmolarity of at least 340 milliosmoles. Preferably the osmolarity is within the range of 340 and 450 milliosmoles, and most preferably about 360 milliosmoles. Preferred media are conventional growth media, e.g., Eagle's media, made hypertonic by the addition of increased amounts of amino acids, preferably twice the normal amino acid content. These amino acids may be added batchwise or on a continuous basis. Conventional media may be periodically infused with excess amino acids to produce amino acid concentrations greater than those normally employed. Alternatively, a previously prepared hypertonic medium may be continuously or intermittently passed through the culture. Improved protein production is also achieved in a batch culture using a hypertonic medium. Any protein-producing cell can benefit from the invention, but genetically modified cells are preferred.

While the method of the invention is generally useful for increasing protein production from conventional protein-producing cell cultures, it is particularly useful when the protein-producing cells are encapsulated within a plurality of capsules having a permeable membrane defining an intracapsular volume. The capsule membrane may include a polymer containing a plurality of primary amine groups salt-bonded to an acidic polysaccharide. The preferred acidic polysaccharide is alginate, while the preferred polymer containing a plurality of primary amine groups is a polypeptide, most preferably polylysine or polyornithine.

An improved growth medium according to the present invention for promoting protein production contains essential salts, nutrients and amino acids necessary for cell growth and mitosis, as do such media as Eagle's modified media, but are modified by the addition of excess amino acids sufficient to increase the osmolarity of the medium to at least about 340 milliosmoles, preferably about 340 to 450 milliosmoles, and most preferably about 360 milliosmoles. Such hypertonic media promote protein production without adversely affecting viability of the cells or their growth rates.

In contrast to conventional belief, the method and medium of the invention are therefore based on the surprising discovery that hypertonic media can promote protein, particularly antibody, production without damaging the viability of the cells. Exceptional antibody yields, having higher specific activity or purity than had previously been possible, are obtained by following the present invention, in either small volume cultures or large, high cell density, production-sized cultures.

Early experiments on the effect of sodium chloride concentration on HeLa and mouse fibroblast cells led to the conclusion that 290 to 330 milliosmoles was the optimum tonicity range for growth of an animal cell culture. However, if one uses the method of the invention, one can achieve antibody yields of 50% of secreted protein, and yields of up to 62% are possible. Because of the high antibody concentration in the secreted protein, purification of the antibody is facilitated, thereby alleviating many of the associated problems and reduce the cost of such purification. Hypertonic media are particularly useful for culturing hybridomas, myelomas, and other continuous mammalian cell protein-producing cultures, yielding higher protein production or secretion levels than is possible with conventional media. Myelomas can be genetically modified to promote production of specific proteins.

Protein-producing cells for use in the invention may be grown in large cultures having cell densities on the order of 10^8 cells/ml in accordance with the procedures disclosed in U.S. patents 4,352,883 and 4,409,331, and in our copending GB application based on U.S.S.N. 579,493 (Agent's ref: 6279) filed on even date herewith, the disclosures of which are incorporated herein by reference. Briefly, the said U.S. patents disclose methods of encapsulating healthy, viable cells and methods of harvesting substances produced by the cells. The copending application discloses that extraordinarily high cell densities may be achieved in encapsulated cultures using conventional media if the oxygen and carbon dioxide requirements are met by sparging a gas of defined oxygen and carbon dioxide content directly through the cultures. Employing these techniques, cultures having a volume on the order of 30 liters and a cell density of 10^8 cells/ml have been produced. Using the process of this invention, such cultures have produced on the order of 3-6 grams of monoclonal antibody.

Figure 5 schematically illustrates apparatus for culturing cells in accordance with the invention. It comprises a 316L stainless steel, electropolished, 50 liter capacity vessel 10 fitted with a headplate 12. A motor 14 drives paddle shaft 16 to rotate paddles 18 and 20 disposed within the culture 22. Culture 22 comprises the hypertonic medium, e.g., as defined hereinafter, and a multiplicity of suspended capsules having membranes permeable to the amino acids, gases, vitamins, ions, etc., contained in the medium. The currently preferred hypertonic medium is modified Eagle's medium containing twice the normal concentration of amino acids and supplemented with 5% by volume serum, e.g., bovine serum. Typically, the capsules are spherical or spheroidal and have a diameter of the order of less than about 2 mm. Capsules having an average diameter of the order of 0.8 mm work well. The gas requirements of the cells are met by passing an oxygen and carbon dioxide-containing gas through a sterile filter 24, air tube 26, and sparging head 28. Sparging head 28 may comprise a 2.5 micron porous porcelain filter. The gas may comprise 95% air and 5% CO_2 (by volume). Gas bubbles pass from the sparging head 28 up through the medium among the capsules. The rate of sparging should be sufficient to maintain the partial pressure of oxygen in the medium substantially equal to the partial pressure of oxygen in the gas. The pressure of oxygen in the medium may thereby be set to a level at, or slightly above that which the cells require for optimal growth. Because of the

serum components in the medium, sparging causes foam to collect in the headspace 30 of vessel 10. However, the capsules protect the cells from dehydration should they temporarily be transported into the foam, and also protect the cells from mechanical damage. Thus, gas sparging through an encapsulated culture can satisfy the need of the increasing cell population for oxygen, thereby enabling extremely high cell densities to be achieved. Gas exiting the culture passes through exit port 32 and filter 34. A typical gas flow rate for a 30 liter culture is 0.2 standard cubic feet per hour (5.7 l/hr).

When practicing the invention in the batch-feeding mode, the hypertonic medium is simply metered into vessel 10 together with microcapsules containing the seed culture, and the culture is grown to maximum density. Alternatively, an isotonic, conventional medium may be employed at the outset, and additional, excess amino acids may be added to the culture by injection one or more times during the growth cycle, e.g., through injection port 36. However, perhaps the best way of practicing the invention is to pass hypertonic medium through the culture by introducing a continuous or intermittent flow of medium into entry port 38, and draining off medium through filter element 40. Filter element 40 may comprise a stainless, microporous mesh having pores smaller than the diameter of the capsules e.g., 50 to 100 microns. Medium may be withdrawn through valve 42. The level of medium in the culture may be observed in transparent site tube 44. A typical rate of medium flow into entry port 38 and out through filter 40 is 4 ml to 12 ml per minute. It is also contemplated that an enriching amino acid solution may be injected into the culture as required to maintain a desired hypertonicity.

The method employed in harvesting protein produced by the cells will depend upon the relationship of the effective molecular dimensions of the protein of interest and the permeability of the capsule membranes. As disclosed in the above-referenced U.S. patents, the permeability of the capsule membranes can be controlled within limits. Details of the currently preferred method of controlling capsule membrane porosity and making uniform capsules are disclosed in our copending GB application based on U.S.S.N. 579,494 (Agent's ref: 6278), the disclosure of which is incorporated herein by reference. If the protein of interest is too large to traverse the membrane, the protein collects within the microcapsules; if it is small enough to traverse the membranes, it will collect in the extracapsular medium.

The following non-limiting examples will further illustrate the invention.

Example 1

This experiment illustrates that increasing the tonicity of the culture medium by the addition of excess amino acids does not alter the viability or rate of cell mitosis of protein producing cells but does cause increased protein production. The cells used in this experiment were a mouse-mouse hybridoma secreting IgG. The hybridomas were encapsulated by a modification of the procedure set forth in the United States Patent No. 4,352,883. More particularly, a suspension containing about 10^6 cells/ml in 1% (w/v) sodium alginate (NaG-Kelco LV) in standard medium was transferred to a jet-head apparatus consisting of a housing having an upper air intake nozzle and an elongate hollow body friction fitted into a stopper. The cell density of the alginate-medium suspension dictates the average number of cells per capsule in the seed culture. A syringe, e.g., a 10 cc syringe, equipped with a stepping pump was mounted atop the housing with a needle, e.g., 0.01 inch (0.25 mm) I.D. Teflon-coated needle, passing through the length of the housing. The interior of the housing was designed such that the top of the needle is subjected to a constant laminar airflow which acts as an air knife. In use, the syringe full of the solution containing the material to be encapsulated is mounted atop the housing, and the stepping pump is activated to incrementally force drops of the solution to the tip of the needle. Each drop is "cut off" by the air stream and falls approximately 2.5-3.5 cm into a 1.2% (w/v) calcium chloride solution, forming gelled masses which are collected by aspiration. The gelled masses may be incubated in three replenished volumes of isotonic saline for gel expansion. In total, the saline expansion takes approximately 11 minutes. Next, a membrane is formed about the gelled masses by contact with a 750 mg/l poly-L-lysine (Sigma Chemical Company, 65,000 dalton molecular weight) in isotonic saline solution. After 12 minutes of reaction, the resulting capsules are washed for 10 minutes with 1.4 g/l solution of CHES (2-cyclohexylamino ethane sulfonic acid) buffer (Sigma) containing 0.2% (w/v) calcium chloride in saline. The capsules are washed for approximately 8 minutes with 0.3% (w/v) calcium chloride in saline, and a second membrane is formed about the capsules by a 10 minute reaction with 105 mg/l polyvinyl amine (Polyscience, 50,000-150,000 dalton molecular weight) in saline. The capsules were washed again with two volumes of isotonic saline over 7 minutes and post-coated with a 7 minute immersion in $5 \times 10^{-2}\%$ (w/v) NaG solution in saline. The capsules were washed for an additional 4 minutes in saline, then the intracapsular volumes were reliquified by two immersions in 55 mM sodium citrate in saline solution, the first for 20 minutes and the second for 6 minutes. The capsules were washed twice in saline and once for 4 minutes in medium. As disclosed generally in U.S. Patent No. 4,409,331, when the capsules are incubated in the growth medium IgG collects within the capsules with only trace quantities detectable in the extracapsular medium. Capsules prepared according to this procedure are substantially impermeable to IgG but permit free traverse of required nutrients thereby permitting cell growth and antibody production within the intracapsular volume.

Table 1 lists the ingredients of a basic, known culture medium while Tables 2 and 3 specify the amino acid and vitamin constituents of this medium. The concentrations in parenthesis in Table 1 represent the modifications made in the iron and amino acid content to form a hypertonic medium according to this invention. Briefly, the iron was increased by a factor of 100 and the amino acid content was doubled. After

formulating the medium, 5% by volume fetal bovine serum is added. The addition of the excess amino acids and ferric nitrate increases the osmolarity of the medium to about 360 milliosmoles. As will be apparent from a review of the constituents of the medium, approximately 4.7% by weight (not including water) comprises amino acid in the normal medium, whereas the hypertonic medium contains approximately 8.9% amino acids. The preferred media of the invention comprise about 7.0% to 12% amino acids.

TABLE 1

Prepared in 40 liter lots

10	<i>Chemical Component</i>	<i>Amount Used</i>	10
	D (+) Glucose	80.0 g	
	NaCl	274.4 g	
15	Na ₂ HPO ₄ (anhydrous)	4.96g	15
	KCl	16.0 g	
	MgSO ₄ (anhydrous)	3.92g	
	NaHCO ₃	88.0 g	
20	<i>Stock Solutions</i>		20
	ZnSO ₄ ·7H ₂ O	8.0 ml	
	conc: 10 ⁻⁶ g/ml		
25	CuSO ₄ ·5H ₂ O	0.04ml	25
	conc: 10 ⁻⁵ g/ml		
	Fe(NO ₃) ₃ ·9H ₂ O	4.0 ml	
30	conc: 10 ⁻⁶ g/ml (10 ⁻⁴ g/ml)		30
	MnCl ₂ ·4H ₂ O	0.4 ml	
35	conc: 10 ⁻⁵ g/ml		35
	Amino Acids	800 ml (1600 ml)	
	conc: 50X		
	Vitamins	800 ml	
40	conc: 50X		40
	PIPES	136.96g	
	L-Tyrosine	1.40g	
	L-Cystine	0.80g	
	CaCl ₂	5.88g	
45	Phenol Red	0.4 g	45
	Q.S. to 40 liters with distilled water.		

TABLE 2

Prepared in 20 liter lots

5	Amino Acid	Amount used	5
	L-alanine	90.0g	
	L-arginine HCl	60.0g	
10	L-aspartic acid	24.0g	10
	L-asparagine H ₂ O	20.0g	
15	L-cysteine HCl·H ₂ O	60.0g	15
	L-glutamine acid	45.0g	
	Glycine	50.0g	
20	L-histidine HCl·H ₂ O	20.0g	20
	L-isoleucine	30.0g	
25	L-leucine	75.0g	25
	L-lysine HCl	90.0g	
	L-methionine	23.0g	
30	L-phenylalanine	25.0g	30
	L-proline	30.0g	
35	L-serine	10.0g	35
	L-threonine	40.0g	
	L-tryptophan	10.0g	
40	L-valine	50.0g	40

Q.s. to 20 liters with distilled water

TABLE 3

Prepared in 10 liter lots

5	VITAMIN	Amount Used	5
	Ascorbic Acid	1.0g	
10	d-Biotin	0.3g	10
	d-Calcium pantothenate	0.5g	
	Choline chloride	0.8g	
15	d-Alpha tocopherol acetate	6 µl	15
	Ergocalciferol	0.5g	
20	Glutathione	0.55g	20
	Myo-Inositol	1.0g	
	Menadione Sodium Bisulfite	0.046g	
25	Methyl linoleate	17 µl	25
	Nicotinamide	0.5g	
30	Pyridoxal-HCl	0.5g	30
	Riboflavin	0.05g	
	Sodium Pyruvate	12.5g	
35	Thiamine HCl	0.52g	35
	Vitamin A	0.05g	
40	Vitamin B12	0.1g	40
	Q.S. to 10 liters with distilled water		

The encapsulated hybridomas were split into four cultures designated 390, 395, 396 and 397. Culture 390, consisting of 6 liters of medium (comprising about 3 liters of settled capsules), was cultured in a 36 liter spinner flask. The initial culture medium was the hypertonic medium containing twice the amino acid content and excess iron. This culture was batch-fed six to eight liters of hypertonic culture medium at days 3, 5, 7, 10, 11, 12, 16, 17, 18, 19, 20 and 21 to maintain the tonicity.

Culture 395, containing 6 liters of encapsulated culture in a stainless steel vessel, was continuously fed a total of 90 liters of normal medium over the 26 day period of the experiment. The amino acid concentration (800 ml) employed resulted in an isotonic medium.

Cultures 396 and 397, each containing 6 liters of encapsulated culture in a stainless steel vessel, were continuously fed 120 liters of medium and additional iron over the 26 day period. Culture 396 received the hypertonic medium with twice the amino acids while culture 397 received isotonic medium. Oxygen/CO₂ was sparged through all encapsulated cultures.

Figure 1 graphically illustrates the number of cells/ml of settled capsules at various times for the four cultures. The cell counts were made using a hemacytometer after disrupting a sample of the capsules. As is evident, the hypertonic medium not only did not hinder hybridoma growth, it may actually have increased the growth rate, an entirely unexpected result.

Figure 2 graphically illustrates the sum of the viable cells/ml of settled capsules as a function of time for the cultures of Figure 1. The viability of the cells in the hypertonic medium is at least as good, if not better, than it is in isotonic medium.

Figure 3 graphically illustrates the increase in antibody production using the hypertonic medium, as a function of time. At day 14, Culture 397, which was fed isotonic medium on a continuous basis, was producing approximately 200 micrograms of antibody per milliliter of capsules, an excellent antibody yield

from a cell culture. In comparison, the cultures grown in the hypertonic medium (390 and 396) were producing approximately 800 micrograms of antibody per milliliter of capsules, a four-fold increase. Antibody concentration was measured by disrupting the capsule membrane and using an ELISA antibody assay. Specifically, a rat-antimouse antibody, coupled to alkaline phosphatase, was reacted with the intracapsular fluid. P-nitrophenyl phosphate was used as a substrate for the alkaline phosphate immunologically coupled to the mouse antibody, and the absorbance of 340 nm was measured.

These experiments show that the increase in antibody content is an effect of the hypertonicity of the medium, not the additional iron. Both Cultures 396 and 397 received identical media having additional iron except 396 received double the amino acids. There was no lack of amino acids in Culture 397 since it was continually fed isotonic medium with amino acids. As is evident from the data, using a hypertonic medium, in this case 360 milliosmoles, rather than the conventional isotonic medium, one can induce increased protein production without degrading cell viability.

Example 2

This example illustrates that, while encapsulation of a cell culture and the addition of an excess of amino acids to make the medium hypertonic greatly increases antibody synthesis, making a medium hypertonic by addition of sodium can yield a small increase in antibody production even for unencapsulated antibody-producing cells.

Three different media were used in this experiment: one having a osmolarity of 250 milliosmoles (hypotonic), a second having an osmolarity of 325 milliosmoles (isotonic), and a third having an osmolarity of 400 milliosmoles (hypertonic). The osmolality of each solution was measured by freezing point depression. Osmolarity of a solution is approximately equal to the osmolality at these concentrations. The media were identical to the base medium set forth in Tables 1 through 3 (without the excess iron or amino acids) except the sodium chloride concentration was varied to change the osmolarity.

Figure 4 graphically illustrates the cell growth as a function of time for the three cultures. as is evident from the Figure, changing the osmolarity of the solution by addition of saline had no significant effect on the cell growth.

Table 4 shows the difference in antibody production caused by modification of the solution osmolarity. Three sets of cultures (A-C), each run in duplicate (a,b), are illustrated in Table 4. All of the cultures were the same hybridoma culture but were in the unencapsulated form.

TABLE 4

		Osmolarity	Ab ($\mu\text{g/ml}$)	Average $\mu\text{g/ml}$	
35		250a	72.9	73	35
		250b	74.1		
	A	325a	72.3	75	
		325b	78.8		
40		400a	79.9	78.8	40
		400b	77.7		
		280a	68.2	67.1	
		250b	66.0		
45		325a	58.6	75.1	45
	B	325b	91.8		
		400a	52.4	70.6	
		400b	88.9		
50		250a	69.7	67.5	50
		250b	65.3		
	C	325a	92.5	87.6	
		325b	82.8		
		400a	79.9	90.3	
55		400b	100.8		55

As is illustrated by the data, increasing the osmolarity of the growth medium by the addition of saline results in protein production that is as good as, or better than, the antibody production from the isotonic medium, and better than the hypotonic medium. As is also evident from the data, the effects are not as dramatic as those illustrated in Figure 3 with media made hypertonic with amino acid addition. Cultures grown in sodium chloride modified hypertonic media thus are characterized by better antibody production than conventional cell cultures. However, the effect of inducing the increase in osmolarity by the addition of amino acids results in a more dramatic and unobvious improvement.

Additional experiments have been performed using protein-producing cells such as human-human

hybridomas which form IgM as well as other mouse-mouse hybridomas which are IgG producers. In all cases, the hypertonic medium produces greater amounts of protein than the isotonic medium. Media containing additional amino acids having an osmolarity of about 350-360 milliosmoles appear optimum, but other hypertonic media which supply sufficient nutrients also promote antibody and other protein

5 production.

Those skilled in the art may determine other modifications or variations of the procedures and products described herein. Such other modifications and variations are included within the following claims.

CLAIMS

- 10 1. A method of promoting protein or antibody production from a protein or antibody-producing cell of mammalian origin comprising the step of culturing the said cell in a hypertonic medium having an osmolarity no less than about 340 milliosmoles. 10
2. The method according to claim 1, wherein the hypertonic medium comprises a medium made
- 15 hypertonic by the addition of an excess of amino acids. 15
3. The method according to claim 2, wherein the excess amino acids are added continuously to maintain the hypertonicity of said medium.
4. The method according to claim 1, 2 or 3, wherein the osmotic pressure of the hypertonic medium is about 340 to 450 milliosmoles.
- 20 5. The method according to any of claims 1 to 3, wherein the osmotic pressure of the hypertonic medium is about 360 milliosmoles. 20
6. The method according to claims 1 to 5, wherein the said cell is of mammalian origin and comprises a genetically modified cell or a hybridoma.
7. The method according to any of claims 1 to 7, wherein the said cell is cultured within a permeable
- 25 capsule membrane disposed within the hypertonic medium. 25
8. A method of producing proteins or antibodies according to claim 1 and substantially as herein described.
9. Proteins or antibodies produced by use of the method claimed in any of claims 1 to 8.
10. A medium for promoting protein production from protein-producing cells, wherein the said medium
- 30 contains essential salts, nutrients, vitamins and amino acids, and wherein the medium further comprises additional amino acids sufficient to increase the osmolarity of the medium to about 340 to 450 milliosmoles. 30
11. The medium according to claim 10, which contains about twice the normal concentration of amino acids.
12. The medium according to claim 11 or claim 12, wherein the amino acids present comprise about 7%
- 35 to 12% of the non-aqueous components in the medium. 35
13. A medium according to claim 10 for promoting protein or antibody production in a cell culture, substantially as herein described by way of example.

